Barclays’s Zimmer Biomet ZBH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-244,300
| Closed | -$26.4M | – | 5521 |
|
|
2024
Q3 | $26.4M | Buy |
+244,300
| New | +$26.7M | 0.01% | 926 |
|
|
2021
Q2 | – | Sell |
-41,200
| Closed | -$6.4M | – | 5110 |
|
|
2021
Q1 | $6.4M | Buy |
+41,200
| New | +$6.38M | ﹤0.01% | 1329 |
|
|
2020
Q3 | – | Sell |
-1,339
| Closed | -$155K | – | 5641 |
|
|
2020
Q2 | $155K | Sell |
1,339
-74,984
| -98% | -$8.64M | ﹤0.01% | 4254 |
|
|
2020
Q1 | $7.49M | Buy |
76,323
+73,645
| +2,750% | +$9.65M | 0.01% | 1180 |
|
|
2019
Q4 | $389K | Buy |
2,678
+1,133
| +73% | +$156K | ﹤0.01% | 4505 |
|
|
2019
Q3 | $206K | Sell |
1,545
-412
| -21% | -$53.2K | ﹤0.01% | 4945 |
|
|
2019
Q2 | $224K | Sell |
1,957
-42,848
| -96% | -$5.02M | ﹤0.01% | 5007 |
|
|
2019
Q1 | $5.55M | Sell |
44,805
-45,526
| -50% | -$5.17M | ﹤0.01% | 1585 |
|
|
2018
Q4 | $9.1M | Sell |
90,331
-56,135
| -38% | -$6.31M | 0.01% | 1209 |
|
|
2018
Q3 | $18.7M | Buy |
146,466
+97,747
| +201% | +$11.6M | 0.01% | 889 |
|
|
2018
Q2 | $5.27M | Sell |
48,719
-8,137
| -14% | -$886K | ﹤0.01% | 1682 |
|
|
2018
Q1 | $6.02M | Sell |
56,856
-5,253
| -8% | -$610K | ﹤0.01% | 1507 |
|
|
2017
Q4 | $7.28M | Buy |
62,109
+46,659
| +302% | +$5.28M | 0.01% | 1383 |
|
|
2017
Q3 | $1.76M | Sell |
15,450
-28,016
| -64% | -$3.23M | ﹤0.01% | 2481 |
|
|
2017
Q2 | $5.42M | Buy |
43,466
+30,797
| +243% | +$3.65M | 0.01% | 1408 |
|
|
2017
Q1 | $1.5M | Sell |
12,669
-18,849
| -60% | -$2.14M | ﹤0.01% | 2350 |
|
|
2016
Q4 | $3.16M | Buy |
31,518
+21,321
| +209% | +$2.29M | ﹤0.01% | 1746 |
|
|
2016
Q3 | $1.29M | Buy |
10,197
+4,120
| +68% | +$509K | ﹤0.01% | 2389 |
|
|
2016
Q2 | $710K | Buy |
6,077
+721
| +13% | +$81.6K | ﹤0.01% | 2905 |
|
|
2016
Q1 | $551K | Sell |
5,356
-54,178
| -91% | -$5.24M | ﹤0.01% | 3068 |
|
|
2015
Q4 | $5.9M | Buy |
59,534
+49,028
| +467% | +$4.8M | 0.01% | 1210 |
|
|
2015
Q3 | $949K | Sell |
10,506
-9,991
| -49% | -$1M | ﹤0.01% | 2759 |
|
|
2015
Q2 | $2.17M | Buy |
20,497
+3,914
| +24% | +$433K | ﹤0.01% | 2160 |
|
|
2015
Q1 | $1.88M | Sell |
16,583
-157,178
| -90% | -$17.9M | ﹤0.01% | 2379 |
|
|
2014
Q4 | $19.1M | Buy |
173,761
+33,372
| +24% | +$3.52M | 0.02% | 792 |
|
|
2014
Q3 | $13.6M | Buy |
140,389
+50,985
| +57% | +$5.01M | 0.01% | 965 |
|
|
2014
Q2 | $8.94M | Buy |
89,404
+24,514
| +38% | +$2.39M | 0.01% | 1242 |
|
|
2014
Q1 | $5.92M | Sell |
64,890
-56,650
| -47% | -$5.22M | 0.01% | 1572 |
|
|
2013
Q4 | $11M | Buy |
121,540
+43,157
| +55% | +$3.73M | 0.01% | 1183 |
|
|
2013
Q3 | $6.24M | Buy |
78,383
+15,759
| +25% | +$1.24M | 0.01% | 1504 |
|
|
2013
Q2 | $4.56M | Buy |
+62,624
| New | +$4.68M | 0.01% | 1701 |
|
Other funds holding ZBH
VCM
VPM
Barclays's ZBH Position: Q1 2026 in Review
Barclays reduced its Zimmer Biomet (ZBH) stake by 6.9% in Q1 2026, selling an estimated $2.92M and leaving 426,256 shares worth $38.5M. The position accounts for 0.01% of the portfolio, ranked #820.
Barclays first reported a position in ZBH in Q2 2013 and has held it in 52 quarters since. The position peaked at $120M in Q3 2023. 912 funds tracked by Wall St. Rank hold ZBH as of Q1 2026.
- Barclays held 426,256 shares of Zimmer Biomet worth $38.5M as of Q1 2026.
- Barclays sold 31,773 Zimmer Biomet shares in Q1 2026, an estimated $2.92M.
- Zimmer Biomet made up 0.01% of Barclays's portfolio in Q1 2026, its #820 holding.
- Barclays first reported a position in Zimmer Biomet in Q2 2013 and has held it in 52 quarters since.
- Barclays's Zimmer Biomet position peaked at $120M in Q3 2023.
- 912 funds tracked by Wall St. Rank held Zimmer Biomet as of Q1 2026.
Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.